The Big Health Care Conundrum: How To Sustainably Unlock The Value Of Diagnostics

Novo holdings panel asks diagnostics industry leaders how to keep the focus on testing post-pandemic

How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? At a recent roundtable event, the CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.

colorful paper with question mark as background.
• Source: Alamy

It is never a bad time to spotlight the value of early and effective diagnosis, the benefits of which extend far beyond the innovator, beyond individual patients and to national economies and wider society. While COVID-19 has wrought unprecedented global disruption, the pandemic has also demonstrated the importance and the value the diagnostics industry has created for society.

That was the contention of Boston Consulting Group’s Ulrik Schulze, in a foreword to a high-level panel hosted by Novo Holdings on “Unlocking the Value of Diagnostics,” which, in the...

Some COVID effects, such as the rise in testing and Emergency Use Authorizations will be temporary, said Schulze, BCG’s global sector leader, biopharma/life sciences. But others, such as increased use...

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.